AR093703A1 - Agente profilactico o terapeutico para el sindrome de sjogren - Google Patents
Agente profilactico o terapeutico para el sindrome de sjogrenInfo
- Publication number
- AR093703A1 AR093703A1 ARP130104456A ARP130104456A AR093703A1 AR 093703 A1 AR093703 A1 AR 093703A1 AR P130104456 A ARP130104456 A AR P130104456A AR P130104456 A ARP130104456 A AR P130104456A AR 093703 A1 AR093703 A1 AR 093703A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic group
- therapeutic agent
- profilactic
- independently
- sjogren syndrome
- Prior art date
Links
- 208000021386 Sjogren Syndrome Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- -1 aryl haloalkyl Chemical group 0.000 abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un agente profiláctico o terapéutico para el Síndrome de Sjogren, que comprende un compuesto representado por medio de la fórmula (1) caracterizado porque n es un número entero de 1 a 3; R es cada uno en forma independiente un grupo alifático, haloalquilo arilo, arilalquilo, alcoxi, cicloalcoxi haloalcoxi, ariloxi, arilalcoxi, alquiltio, un átomo de halógeno, nitro, ciano, hidroxi, NR¹CO₂R², C(O)N(R¹)₂, C(O)R², CO₂R², OC(O)N(R¹)₂, OC(O)R², N(R¹)₂ o NR¹C(O)R²; o una forma de dos grupos R adyacentes, junto con un átomo unido al mismo, un anillo de 5 a 7 miembros condensado, saturado, insaturado o parcialmente insaturado que tiene 0, 1 ó 2 heteroátomos seleccionados entre N, O y S; R¹ es cada uno en forma independiente un átomo de hidrógeno o un grupo alifático; y R² es un grupo alifático; o una sal aceptable para uso farmacéutico de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733176P | 2012-12-04 | 2012-12-04 | |
| US201361894641P | 2013-10-23 | 2013-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093703A1 true AR093703A1 (es) | 2015-06-17 |
Family
ID=49885350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104456A AR093703A1 (es) | 2012-12-04 | 2013-12-03 | Agente profilactico o terapeutico para el sindrome de sjogren |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8815887B2 (es) |
| AR (1) | AR093703A1 (es) |
| TW (1) | TW201438717A (es) |
| UY (1) | UY35165A (es) |
| WO (1) | WO2014088113A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210154292A1 (en) * | 2019-11-21 | 2021-05-27 | Chemocentryx, Inc. | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| CN113892460A (zh) * | 2021-09-29 | 2022-01-07 | 滨州医学院 | Nod-b6重组近交系小鼠模型的构建方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ536504A (en) | 2002-05-24 | 2008-04-30 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| DE60314175T2 (de) | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| GB0526255D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526252D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526257D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526445D0 (en) | 2005-12-23 | 2006-02-08 | Novartis Ag | Organic compounds |
| BRPI0807836A2 (pt) | 2007-02-06 | 2014-08-05 | Novartis Ag | " derivados de 1-benzenossulfonil-1h-indol como inibidores da atividade de ccr9 ". |
| PT2250161E (pt) | 2008-01-18 | 2014-01-21 | Atopix Therapeutics Ltd | Compostos tendo atividade antagonista de crth2 |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP6249966B2 (ja) | 2012-02-29 | 2017-12-20 | ケモセントリックス， インコーポレイテッド | アザ−アリール１ｈ−ピラゾール−１−イルベンゼンスルホンアミド |
-
2013
- 2013-12-03 UY UY0001035165A patent/UY35165A/es unknown
- 2013-12-03 US US14/095,026 patent/US8815887B2/en not_active Expired - Fee Related
- 2013-12-03 AR ARP130104456A patent/AR093703A1/es unknown
- 2013-12-03 TW TW102144170A patent/TW201438717A/zh unknown
- 2013-12-03 WO PCT/JP2013/082902 patent/WO2014088113A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20140155437A1 (en) | 2014-06-05 |
| UY35165A (es) | 2014-06-30 |
| TW201438717A (zh) | 2014-10-16 |
| US8815887B2 (en) | 2014-08-26 |
| WO2014088113A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6811860A2 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| CR20150085A (es) | Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| NI201500030A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| EA201492214A1 (ru) | Ингибиторы вируса гепатита с | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR093767A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos | |
| CR20150268A (es) | Compuestos novedosos | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
| CR20140135A (es) | Nuevos derivados de aril-quinolina | |
| CO6351793A2 (es) | \"derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| CL2017000293A1 (es) | Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) | |
| ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos | |
| AR091520A1 (es) | Inhibidores piranopiridona de tanquirasa | |
| BR112015028871A2 (pt) | novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona | |
| AR093703A1 (es) | Agente profilactico o terapeutico para el sindrome de sjogren | |
| UY35390A (es) | Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen | |
| CR20150160A (es) | Derivados de macrólidos, su preparación y su uso terapéutico | |
| AR090215A1 (es) | Compuestos de espirohidantoina y su uso como moduladores selectivos del receptor de androgenos | |
| AR093168A1 (es) | COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |